{
  "catalogId": "31dce6bc-3f36-48dc-9ad1-1c4f738ae4a5",
  "name": "TIBSOVO",
  "status": "draft",
  "category": "29C",
  "registrationValidity": "valid",
  "registrationNumber": "179 35 38216 99",
  "treatmentDescriptions": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
  "termsOfIssue": "",
  "form": "film coated tablets",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "IVOSIDENIB",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XX62",
      "name": "IVOSIDENIB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "TIBSOVO 250MG 50 tab",
      "manufacturer": {
        "name": "",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 50.0,
        "unit": "units"
      },
      "packagingDescription": "BOTTLE HDPE",
      "shelfLife": "60",
      "storageConditions": "",
      "codes": {
        "moh": "20988"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": "",
        "retailMargin": "",
        "maxRetailPrice": "",
        "maxPriceWithVAT": ""
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:43.206671"
  }
}